EUVIMEDEUVIMED entdecken
Crossref

Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions

Xin Ding, Yang Zhang, Songshen Chu, Song Huang, Jiajia Wang iD, Xia Li

Molecular Pharmaceutics · 06.10.2025 · 22 (10) · 6151-6162

DOI: 10.1021/acs.molpharmaceut.5c00856 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 15.09.2025. Verfasst von Xin Ding und 5 weiteren Autor:innen. Beteiligte Einrichtung: Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475000, China. Hauptthemen laut MEDLINE: Macrophages. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Henan Medical Science and Technique Foundation, National Natural Science Foundation of China, Key Science and Technology Program of Kaifeng City in Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor macrophages (CAR-Ms), which are genetically engineered, have application prospects in solid tumor therapy because of the prominent role of macrophages in the tumor microenvironment. Recently, non-natural sugar metabolic labeling based on bioorthogonal reactions has emerged as a research hotspot in targeted tumor therapy. In this study, 4T1 cells and M1 macrophages were incubated with Ac4GalBCN and Ac4ManNAz, respectively, to equip the cell surfaces with -BCN and -N3 groups. These modifications enhanced the proximity between these two kinds of cells and promoted phagocytosis and cytokine release. Moreover, compared to other groups, the bioorthogonal labeling group exhibited heightened tumor-targeted effects and antitumor phagocytic activity against 4T1 cells in vivo. Addition of the small-molecule inhibitor RRx-001 further improved the synergistic effect on phagocytosis and immune cell phenotypes in tumors. In summary, our study highlights the metabolic labeling strategy as a potent approach to promote M1 macrophage-mediated antitumor responses within the tumor environment, providing a novel means for the development of therapeutic strategies tailored for solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesAnimalsMicePhagocytosisTumor MicroenvironmentCell Line, TumorFemaleMice, Inbred BALB CReceptors, Chimeric AntigenHumansAntineoplastic AgentsCytokines

Stichwörter der Autor:innen

bioorthogonal reactionmacrophagemetabolic glycan labelingtumor microenvironment

Substanzen

Receptors, Chimeric AntigenAntineoplastic AgentsCytokines

Autor:innen und Institutionen

  • Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng 475000, China.
  • College of Pharmacy, Henan University, Kaifeng 475000, China.

ORCID-Profile: Jiajia Wang

Förderung

  • Henan Medical Science and Technique Foundation
  • National Natural Science Foundation of China
  • Key Science and Technology Program of Kaifeng City in Henan Province
  • Henan Province colleges and universities young backbone teacher training program

Zitieren

APA

Ding, X., Zhang, Y., Chu, S., Huang, S., Wang, J., & Li, X. (2025). Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions. Molecular Pharmaceutics, 22(10), 6151-6162. https://doi.org/10.1021/acs.molpharmaceut.5c00856

Vancouver

Ding X, Zhang Y, Chu S, Huang S, Wang J, Li X. Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions. Molecular Pharmaceutics. 2025;22(10):6151-6162. doi:10.1021/acs.molpharmaceut.5c00856

BibTeX
@article{Ding2025,
  author = {Ding, Xin and Zhang, Yang and Chu, Songshen and Huang, Song and Wang, Jiajia and Li, Xia},
  title = {Enhancement of Targeted and Antitumor Effects of M1 Macrophages Based on Bioorthogonal Reactions},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {10},
  pages = {6151--6162},
  doi = {10.1021/acs.molpharmaceut.5c00856}
}
Kostenlos starten →